Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02394379 · ClinicalTrials.gov registry record
Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL
A clinical trial, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- 600
- Enrollment target
NCT02394379: Completed study, sponsored by Bausch & Lomb Incorporated.
NCT02394379 is a clinical trial that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02394379 has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
Study Summary
To evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery.
Primary Outcome
IOL vaulting is position change such as clinically significant anterior vaulting, clinically significant tilt, and secondary surgical intervention related to such vaulting. The proportion of study eyes experiencing vaulting will be estimated by Kaplan-Meier method.
Interventions
- DEVICE Trulign™ Toric IOL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2015-03-19 |
| Est. Completion | 2019-08-05 |
What the finished NCT02394379 record still lists
NCT02394379 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Trulign™ Toric IOL is the first listed.
NCT02394379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02394379 about?
NCT02394379 is a clinical study titled "Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL". To evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery.
What is the current status of trial NCT02394379?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2015-03-19. Estimated completion is 2019-08-05.
What interventions are being tested in trial NCT02394379?
The interventions under investigation include: Trulign™ Toric IOL (DEVICE).
Who is sponsoring clinical trial NCT02394379?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI